Pharmacist Checklist - Guidance for dispensing Toctino▼ (alitretinoin)

Toctino belongs to the retinoid class of drugs that cause severe birth defects. Fetal exposure to Toctino, even for short periods of time, presents a high risk of congenital malformations and miscarriage.

Toctino is therefore strictly contraindicated during pregnancy and in women of childbearing potential, unless all conditions in the Toctino Pregnancy Prevention Programme are fulfilled.

A negative pregnancy test, issuing a prescription and dispensing Toctino should ideally occur on the same day.

If you are aware that a pregnancy has occurred in a woman treated with Toctino, treatment should be stopped immediately and the woman should be promptly referred to the prescribing doctor.

If you are aware that a female patient has become pregnant within one month after stopping Toctino, she should be referred to her prescribing doctor.

As pharmacist, you should only dispense Toctino after checking the following information:

For women of child-bearing potential:	
In order to support regular follow up, including pregnancy testing and monitoring, the prescription for Toctino should ideally be limited to a 30-day supply.	
All patients should be instructed:	
Never to give the Toctino to another person.	
To return any unused capsules to their pharmacist at the end of treatment.	
Not to donate blood during Toctino therapy and for one month after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient.	

This medicinal product is subject to additional monitoring. Pregnancies occurring during treatment and within 1 month following discontinuation of treatment should be reported to the MHRA and the company listed in the patient information leaflet who will follow up with you to record the pregnancy outcome. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221 441

March 2019
UK/ART/0001/18